Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance
Open Access
- 1 May 2008
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 18 (3) , 487-491
- https://doi.org/10.1111/j.1525-1438.2007.01039.x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasmsCancer Biology & Therapy, 2006
- Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomasGynecologic Oncology, 2006
- Origins and molecular pathology of ovarian cancerLaboratory Investigation, 2005
- Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian CarcinogenesisThe American Journal of Surgical Pathology, 2005
- Assay-Assisted Treatment Selection for Women with Breast or Ovarian CancerPublished by Springer Nature ,2003
- p53 mutation does not affect prognosis in ovarian epithelial malignanciesThe Journal of Pathology, 2001
- p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian CarcinomaJournal of Clinical Oncology, 2000
- p53 Mutations and Expression in Ovarian CancersInternational Journal of Gynecological Pathology, 1999
- Correlation between Extreme Drug Resistance Assay and Response to Primary Paclitaxel and Cisplatin in Patients with Epithelial Ovarian CancerGynecologic Oncology, 1998
- p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical studyBritish Journal of Cancer, 1997